Acquiring Company
Acrivon Therapeutics
Acquired Company
Aqilion AB
Watertown
SwedenBiotechnologyHealth CareMedicalTherapeuticsBiopharmaBiotechnologyHealth CareTherapeuticsPharmaceuticalDescription
On November 6, 2026, Acrivon Therapeutics, Inc. announced its acquisition of Aqilion AB's asset programs for the development of oral JAK1 inhibitors and a PKCθ inhibitor preclinical program. This acquisition empowers Acrivon to enhance its therapeutic offerings for the treatment of inflammatory and autoimmune diseases. The agreement includes the complete transfer of relevant assets without additional milestone or royalty payment obligations.
Who to call at Acrivon Therapeutics, and when
When Acrivon Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Acrivon Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Acrivon Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Acrivon Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Acrivon Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Aqilion AB?
Aqilion AB was acquired by Acrivon Therapeutics, based in Watertown. The deal was reported on November 6, 2026. Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. Acrivon Therapeutics is publicly traded (ACRV) and operates in Biotechnology.
When did Acrivon Therapeutics acquire Aqilion AB?
Acrivon Therapeutics's acquisition of Aqilion AB was reported on November 6, 2026. On November 6, 2026, Acrivon Therapeutics, Inc. announced its acquisition of Aqilion AB's asset programs for the development of oral JAK1 inhibitors and a PKCθ inhibitor preclinical program. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Aqilion AB do?
Aqilion AB is a Swedish public limited company specializing in the development of innovative therapeutics for inflammatory and autoimmune diseases. The company is dedicated to advancing research and development in the field of pharmaceuticals. It is privately held, operating in Biotechnology, and is based in Sweden.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.